Febrile Neutropenia

Diagnose febrile neutropenia when oral temperature is at least 38.3°C (101°F) once, or at least 38.0°C (100.4°F) sustained for 1 hour, with ANC 500/µL or lower, or ANC 1,000/µL or lower that is expected to decrease to 500/µL or lower within 48 hours.BMJ+1BMJFebrile neutropenia - Symptoms, diagnosis and treatment | BMJ Best Practice USOxford AcademicClinical Practice Guideline for the Use of Antimicrobial Agents ... This threshold includes patients at the anticipated chemotherapy nadir, not only those with an already documented ANC below 500/µL.

Treat febrile neutropenia as an oncologic emergency. Obtain clinically indicated diagnostic specimens promptly, but administer empiric antibacterial therapy within 2 hours of presentation; microbiologic confirmation is not required because many episodes have no identifiable bacterial source despite the need for antibacterial treatment.BMJ+2BMJFebrile neutropenia - Symptoms, diagnosis and treatment | BMJ Best Practice USScienceDirectOncologic Emergencies: The Fever With Too Few Neutrophils - ScienceDirectOxford AcademicClinical Practice Guideline for the Use of Antimicrobial Agents ...

Prioritize physiologic stabilization before outpatient-risk assessment. Hemodynamic instability, respiratory compromise, altered mental status, or other features of critical illness should direct immediate inpatient escalation and broad empiric treatment rather than use of a low-risk pathway. Septic shock and comorbidity substantially increase reported mortality risk in febrile neutropenia.PubMedPubMedClinical prediction models for febrile neutropenia and its outcomes: a systematic review - PMC

Perform a complete examination targeted to occult infection sites and treatment complications, including the oral cavity, skin and soft tissue, vascular-access sites, perineum, lungs, abdomen, and wounds. In neutropenic patients, local inflammatory findings may be limited; absence of a clear source does not reduce the need for empiric antibacterial treatment.ScienceDirect+1ScienceDirectOncologic Emergencies: The Fever With Too Few Neutrophils - ScienceDirectOxford AcademicClinical Practice Guideline for the Use of Antimicrobial Agents ...

Obtain a complete blood count with differential to establish ANC and assess concurrent cytopenias. Measure renal function, liver tests, and electrolytes because these define acute organ involvement and provide a baseline for antimicrobial selection and subsequent toxicity monitoring. Blood cultures should include a peripheral sample; obtain urine, wound, or pus cultures when those sites are clinically implicated.NatureNatureMicrobiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting | Scientific Reports

Use imaging selectively rather than as a universal screening test. Obtain chest imaging for respiratory symptoms or signs; high-resolution chest CT is used when fungal infection is clinically suspected. In persistent neutropenic fever, imaging and microbiology should be revisited because an initially occult invasive fungal process may emerge after broad-spectrum antibacterial exposure.Nature+1NatureMicrobiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting | Scientific ReportsOxford Academic2016 Update by the Infectious Diseases Society of America

Risk stratification should integrate current clinical condition, cancer type and treatment context, infection history, baseline laboratory and radiographic findings, and anticipated duration or depth of neutropenia. Talcott, MASCC, and CISNE are established adult complication-risk models, but they use different predictors and should be interpreted within the presenting clinical context.Nature+2NatureIn-hospital mortality prognostication for cancer patients with febrile neutropenia | Communications MedicineScienceDirectEmergency management of fever and neutropenia in children with cancer: A review - ScienceDirectPubMedClinical prediction models for febrile neutropenia and its outcomes: a systematic review - PMC

High-risk management is appropriate for patients with physiologic instability, severe clinical illness, major comorbidity, concerning vital-sign or laboratory abnormalities, or a presentation requiring inpatient diagnostic or supportive care. These patients should receive inpatient empiric antibacterial therapy and serial reassessment for a source, resistance, organ dysfunction, and escalation needs.Nature+1NatureIn-hospital mortality prognostication for cancer patients with febrile neutropenia | Communications MedicinePubMedClinical prediction models for febrile neutropenia and its outcomes: a systematic review - PMC

Outpatient management is a risk-stratified option rather than a default. ASCO/IDSA guidance addresses outpatient treatment in adults with malignancy, and evidence supports reduced-intensity treatment for selected low-risk pediatric episodes; selection depends on a structured low-risk assessment and the ability to safely execute follow-up and reassessment.BMJ+4BMJFebrile neutropenia - Symptoms, diagnosis and treatment | BMJ Best Practice USThe LancetRisk stratification in children with cancer and febrile neutropeniaThe LancetRisk stratification in children with cancer and febrile ...ScienceDirectEmergency management of fever and neutropenia in children with cancer: A review - ScienceDirectPubMedClinical prediction models for febrile neutropenia and its outcomes: a systematic review - PMC

All patients meeting febrile neutropenia criteria require urgent empiric antibacterial therapy. The immediate objective is early coverage of likely bacterial pathogens during severe neutrophil impairment, not proof of infection before treatment. The guideline timing target is within 2 hours of presentation.Oxford AcademicOxford AcademicClinical Practice Guideline for the Use of Antimicrobial Agents ...

Antibiotic selection should be informed by risk category, current clinical severity, prior infection history, local resistance patterns, and suspected site of infection. The clinical picture should guide antibiotic choices after risk stratification; culture and susceptibility results then permit narrowing or redirection when an organism or focus is established.The Lancet+2The LancetImpact of time to antibiotics on clinical outcome in ...NatureMicrobiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting | Scientific ReportsOxford AcademicClinical Practice Guideline for the Use of Antimicrobial Agents ...

Persistent fever alone during ongoing neutropenia does not establish antibacterial failure, but it requires repeat assessment for a missed focus, resistant pathogen, drug fever, mucosal-barrier injury, and invasive fungal infection. If fever persists after about 1 week of broad-spectrum antibacterial therapy during neutropenia, add empiric antifungal therapy or pursue a preemptive antifungal strategy guided by clinical and diagnostic findings.NEJM+1NEJMManagement of Fever in Patients with Cancer and ...Oxford Academic2016 Update by the Infectious Diseases Society of America

Monitor serial vital signs, clinical examination findings, ANC trajectory, renal and hepatic function, and culture results. Reassess promptly for new pulmonary, skin, catheter-associated, urinary, abdominal, or wound findings because the source may be absent at presentation and later become clinically apparent.Nature+1NatureMicrobiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting | Scientific ReportsScienceDirectOncologic Emergencies: The Fever With Too Few Neutrophils - ScienceDirect

Before the next chemotherapy cycle, review the episode in the context of regimen-associated febrile neutropenia risk and patient factors. Risk for febrile neutropenia varies with chemotherapy regimen intensity and is modified by age, cancer type, comorbidities, prior infection history, delayed antibiotic exposure, and vital-sign or laboratory abnormalities.Nature+2NatureIn-hospital mortality prognostication for cancer patients with febrile neutropenia | Communications MedicineScienceDirectRisk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review - ScienceDirectESMOESMO Clinical Practice Guideline: Febrile Neutropaenia

A prior febrile neutropenia episode should prompt coordination between oncology and the treating acute-care team to document the episode’s severity, microbiology, suspected source, duration of neutropenia, and treatment complications. These data determine whether subsequent cycles require modification of the supportive-care plan or more intensive surveillance; the specific intervention should follow the planned regimen and oncology protocol.Nature+1NatureIn-hospital mortality prognostication for cancer patients with febrile neutropenia | Communications MedicineScienceDirectRisk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review - ScienceDirect